Skip to content

Ondansetron

FDA-approved product (tablet, orally disintegrating, oral), marketed as Ondansetron, Zofran Odt, Zuplenz and 6 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Ondansetron
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Chemotherapy-induced nausea and vomiting
  • Nausea
  • Nausea and vomiting
  • Post operative nausea and vomiting
  • Radiation-induced nausea and vomiting
  • Vomiting

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Serotonin (5ht3) antagonists
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA45.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli26.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae24.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis59.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.6 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.9 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Ondansetron with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Feasibility and Safety of a Pediatric ERAS Protocol for Laparoscopic Appendectomy

    NCT07643285 · start 2026-06-15

    Registered record
    Registry ID
    NCT07643285
    Conditions
    Appendectomy, Laparoscopic; Acute Appendicitis; Pediatric Surgery; ERAS
    Interventions
    Comprehensive 20-Item Pediatric ERAS Protocol
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2026-06-15
    Completion
    2027-08
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAppendectomy, Laparoscopic; Acute Appendicitis; Pediatric Surgery; ERAS
    InterventionComprehensive 20-Item Pediatric ERAS Protocol
    PhaseNot applicable
    Registry statusRecruiting
  • The Efficacy and Safety of Liposomal Bupivacaine in Relieving Postoperative Pain After Video-assisted Thoracoscopic Surgery

    NCT07432711 · start 2026-03-02

    Registered record
    Registry ID
    NCT07432711
    Conditions
    Video-assisted Thoracoscopic Surgery (VATS); Pain Management; Liposomal Bupivacaine; Local Injection
    Interventions
    Bupivacaine hydrochloride; Liposomal bupivacaine plus bupivacaine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2026-03-02
    Completion
    2027-06-30
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVideo-assisted Thoracoscopic Surgery (VATS); Pain Management; Liposomal Bupivacaine; Local Injection
    InterventionBupivacaine hydrochloride; Liposomal bupivacaine plus bupivacaine
    PhaseNot applicable
    Registry statusRecruiting
  • Effects of Rectal Indomethacin Suppository on Postoperative CRBD in Patients Undergoing LRP

    NCT07607990 · start 2026-01-01

    Registered record
    Registry ID
    NCT07607990
    Conditions
    Prostate Cancer (Post Prostatectomy); Perioperative Anesthetic; Catheter-related Bladder Discomfort (CRBD)
    Interventions
    Indomethacin suppository
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2026-01-01
    Completion
    2026-12-31
    Enrolment
    130

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer (Post Prostatectomy); Perioperative Anesthetic; Catheter-related Bladder Discomfort (CRBD)
    InterventionIndomethacin suppository
    PhaseNot applicable
    Registry statusRecruiting
  • Preventative Effect of Combining Dexamethasone with Ondansetron on Postoperative Nausea, Vomiting and Shivering in Children Undergoing Caudal Anesthesia on Hypospadias Surgery

    NCT06747975 · start 2025-01-01

    Registered record
    Registry ID
    NCT06747975
    Conditions
    Caudal Anesthesia
    Interventions
    Dexamethasone and Ondansetron; Bupivacaine + saline
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2025-01-01
    Completion
    2026-03-01
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCaudal Anesthesia
    InterventionDexamethasone and Ondansetron; Bupivacaine + saline
    PhasePhase 4
    Registry statusNot yet recruiting
  • The Role of Levosimendan as Inotropic Agent in Acute Aluminum Phosphide-induced Cardiotoxicity

    NCT06478667 · start 2024-12-20

    Registered record
    Registry ID
    NCT06478667
    Conditions
    Acute Myocarditis
    Interventions
    levosemindan
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2024-12-20
    Completion
    2025-01-20
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Myocarditis
    Interventionlevosemindan
    PhasePhase 3
    Registry statusCompleted
  • Comparative Efficacy of Dexamethasone - Ondansetron Versus Dexamethasone - Haloperidol in Reducing PONV

    NCT06428084 · start 2023-11-01

    Registered record
    Registry ID
    NCT06428084
    Conditions
    Laparoscopic Cholecystectomy
    Interventions
    Ondansetron; Haloperidol
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2023-11-01
    Completion
    2024-02-28
    Enrolment
    38

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLaparoscopic Cholecystectomy
    InterventionOndansetron; Haloperidol
    PhasePhase 2
    Registry statusCompleted
  • ESPB vs.Combination of ESPB and Superficial PIPB in Cardiac Surgery

    NCT05191953 · start 2022-01-26

    Registered record
    Registry ID
    NCT05191953
    Conditions
    Anesthesia; Analgesia; Acute Pain; Patient Controlled Analgesia
    Interventions
    Bilateral ultrasound-guided ESPB; Bilateral ultrasound-guided ESPB and superficial PIPB
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2022-01-26
    Completion
    2022-06-25
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnesthesia; Analgesia; Acute Pain; Patient Controlled Analgesia
    InterventionBilateral ultrasound-guided ESPB; Bilateral ultrasound-guided ESPB and superficial PIPB
    PhaseNot applicable
    Registry statusCompleted
  • Multi-DOSE Oral Ondansetron for Pediatric Acute GastroEnteritis

    NCT03851835 · start 2019-09-14

    Registered record
    Registry ID
    NCT03851835
    Conditions
    Acute Gastroenteritis; Viral Illness; Vomiting; Diarrhea
    Interventions
    Ondansetron Oral Solution; Oral Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2019-09-14
    Completion
    2024-07-06
    Enrolment
    1,030

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Gastroenteritis; Viral Illness; Vomiting; Diarrhea
    InterventionOndansetron Oral Solution; Oral Placebo
    PhasePhase 3
    Registry statusCompleted
  • Mode of Action of Ondansetron, a 5-HT Receptor 3 Antagonist, in Lactulose Induced Diarrhoea

    NCT03833999 · start 2018-10-16

    Registered record
    Registry ID
    NCT03833999
    Conditions
    Motility Disorder of Intestine; Ondansetron; Small Bowel Water
    Interventions
    Ondansetron 8mg; abdominal MRI; Lactulose; Placebo oral capsule
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2018-10-16
    Completion
    2019-06-27
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMotility Disorder of Intestine; Ondansetron; Small Bowel Water
    InterventionOndansetron 8mg; abdominal MRI; Lactulose; Placebo oral capsule
    PhasePhase 4
    Registry statusCompleted
  • Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants

    NCT03511118 · start 2018-10-04

    Registered record
    Registry ID
    NCT03511118
    Conditions
    Lactating Women on Select DOI; Breastfed Infants of Mothers on Select DOI
    Interventions
    Tranexamic acid (TXA); labetalol; metformin; nifedipine; clindamycin; oxycodone; azithromycin; escitalopram; sertraline; ondansetron; Ciprofloxacin; Doxycycline; Levofloxacin; Methylphenidate; Sumatriptan; Citalopram; Cyclobenzaprine; Furosemide; Gabapentin; Hydrochlorothiazide; Hydroxyurea; Rosuvastatin; Topiramate; Trazodone; Valganciclovir; Venlafaxine; Verapamil; Remdesivir; Anakinra; Tocilizumab; Fluvoxamine; Amoxicillin; Bupropion; Duloxetine; Hydrocodone; Levetiracetam; Paroxetine; Buprenorphine
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2018-10-04
    Completion
    2028-07-31
    Enrolment
    1,600

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLactating Women on Select DOI; Breastfed Infants of Mothers on Select DOI
    InterventionTranexamic acid (TXA); labetalol; metformin; nifedipine +34 more
    PhaseNot recorded
    Registry statusRecruiting
  • Noninvasive Markers of Functional Nausea in Children

    NCT03593811 · start 2018-08-03

    Registered record
    Registry ID
    NCT03593811
    Conditions
    Nausea
    Interventions
    Questionnaires; 4 channel electrogastrogram (EGG); 36 channel high resolution electrogastrogram (HR-EGG); Magnetogastrogram (MGG); Electrocardiogram (EKG); Ondansetron; Cyproheptadine Oral Tablet
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Completed
    Start
    2018-08-03
    Completion
    2021-04-02
    Enrolment
    42

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNausea
    InterventionQuestionnaires; 4 channel electrogastrogram (EGG); 36 channel high resolution electrogastrogram (HR-EGG); Magnetogastrogram (MGG) +3 more
    PhaseEarly phase 1
    Registry statusCompleted
  • Radiosensitizing Effect of Nelfinavir in Locally Advanced Carcinoma of Cervix

    NCT03256916 · start 2018-01-16

    Registered record
    Registry ID
    NCT03256916
    Conditions
    Carcinoma Cervix,Stage III
    Interventions
    Nelfinavir; Cisplatin; Pelvic EBRT and Brachytherapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2018-01-16
    Completion
    2024-05-28
    Enrolment
    348

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoma Cervix,Stage III
    InterventionNelfinavir; Cisplatin; Pelvic EBRT and Brachytherapy
    PhasePhase 3
    Registry statusCompleted
  • Comparison of IV Fluid Loading and Ondansetron in Reduction of PONV After LC

    NCT03141645 · start 2017-06-20

    Registered record
    Registry ID
    NCT03141645
    Conditions
    Postoperative Nausea; Postoperative Vomiting; Postoperative Nausea and Vomiting
    Interventions
    Fluid loading; Ondansetron
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2017-06-20
    Completion
    2019-04-01
    Enrolment
    171

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPostoperative Nausea; Postoperative Vomiting; Postoperative Nausea and Vomiting
    InterventionFluid loading; Ondansetron
    PhaseNot applicable
    Registry statusCompleted
  • Real-time Decision Support for Postoperative Nausea and Vomiting (PONV) Prophylaxis

    NCT02625181 · start 2016-07

    Registered record
    Registry ID
    NCT02625181
    Conditions
    Postoperative Nausea and Vomiting
    Interventions
    Automated recommendation at the start of the case; Automated notification at the start of surgery; Preoperative recommendations: by email; Automated notification at the end of surgery; Anesthesia Information Management System (AIMS); Perioperative Data Warehouse (PDW); General anesthesia; Elective surgery; Propofol; Sevoflurane; Isoflurane; Desflurane; Scopolamine; Droperidol; Haloperidol; Dexamethasone; Promethazine; Meclizine; Aprepitant; Metoclopramide; Fentanyl; Sufentanil; Alfentanil; Remifentanil; Morphine; Meperidine; Hydromorphone; Methadone; Oxycodone; Oxymorphone; Hydrocodone; Ketamine; Ondansetron; Granisetron; Dolasetron mesylate; Palonosetron; Tropisetron; Ramosetron
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2016-07
    Completion
    2017-11-30
    Enrolment
    27,034

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPostoperative Nausea and Vomiting
    InterventionAutomated recommendation at the start of the case; Automated notification at the start of surgery; Preoperative recommendations: by email; Automated notification at the end of surgery +34 more
    PhaseNot applicable
    Registry statusCompleted
  • The Effect of Acupuncture in Chemotherapy-induced Nausea and Vomiting

    NCT02369107 · start 2015-02

    Registered record
    Registry ID
    NCT02369107
    Conditions
    Chemotherapy-induced Nausea and Vomiting
    Interventions
    Verum acupuncture and medicine; Sham acupuncture and medicine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2015-02
    Completion
    2016-12
    Enrolment
    136

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChemotherapy-induced Nausea and Vomiting
    InterventionVerum acupuncture and medicine; Sham acupuncture and medicine
    PhaseNot applicable
    Registry statusUnknown